Table 1.
Associations between midkine, syndecan-3 protein expression and clinicopathologic factors in pancreatic cancers n (%)
| Factor | Midkine positive cases | Syndecan-3 positive cases |
| Age (yr) | ||
| > 60 (n = 26) | 17 (65.4) | 17 (65.4) |
| ≤ 60 (n = 16) | 9 (56.3) | 7 (43.8) |
| Sex | ||
| Female (n = 16) | 12 (75.0) | 10 (62.5) |
| Male (n = 26) | 14 (53.8) | 14 (53.8) |
| CA19-9 (n = 42) | ||
| >37 U/mL (n = 24) | 16 (66.7) | 12 (50.0) |
| ≤ 37 U/mL (n = 18) | 12 (66.7) | 10 (55.6) |
| Histological grade | ||
| I (n = 5) | 4 (80.0) | 2 (40.0) |
| II (n = 22) | 16 (72.7) | 15 (68.2) |
| III (n = 15) | 7 (46.7) | 7 (46.7) |
| Tumor size | ||
| T ≤ 2 cm (n = 10) | 4 (40.0) | 3 (30.0)a |
| 2 cm < T ≤ 5 cm (n = 24) | 14 (58.3) | 15 (62.5)a |
| T > 5 cm (n = 8) | 8 (100.0) | 7 (87.5)a |
| Lymph node metastasis | ||
| Negative (n = 17) | 7 (41.2)a | 7 (41.2) |
| Positive (n = 25) | 19 (76.0)a | 17 (68.0) |
| Distant metastasis | ||
| Negative (n = 36) | 21 (58.3) | 19 (52.8) |
| Positive (n = 6) | 5 (83.3) | 5 (83.3) |
| TNM grade | ||
| I + II (n = 21) | 9 (42.9)b | 10 (47.6) |
| III (n = 16) | 13 (81.3)b | 10 (62.5) |
| IV (n = 5) | 5 (100.0)b | 5 (100.0) |
a
P < 0.05,
b
P < 0.01 vs negative cases.